Expression of chemokines and chemokine receptors in lesional and nonlesional upper skin of patients with atopic dermatitis Eva Gros, MSc, Caroline Bussmann,

Slides:

Advertisements

Similar presentations

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Advertisements

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology Saakshi Khattri, MD, Avner.

Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence Mariya Rozenblit, BA, Mayte Suarez-Farinas,

Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2 Natalija Novak, MD, Nihal Mete, MD, Caroline.

Mechanisms of IFN-γ–induced apoptosis of human skin keratinocytes in patients with atopic dermatitis Ana Rebane, PhD, Maya Zimmermann, PhD, Alar Aab,

Natalija Novak, MD Journal of Allergy and Clinical Immunology

Flow cytometry imaging identifies rare TH2 cells expressing thymic stromal lymphopoietin receptor in a “proallergic” milieu Amanda J. Reefer, MS, Kathryn.

RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications Mayte.

Cell-to-cell contact between activated CD4+ T lymphocytes and unprimed monocytes interferes with a TH1 response Miriam Wittmann, MD, Mareike Alter, Tanja.

Reduced IFN-γ receptor expression and attenuated IFN-γ response by dendritic cells in patients with atopic dermatitis Eva Gros, MSc, Susanne Petzold,

Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis Mayte Suárez-Fariñas, PhD,

Atopic dermatitis: Age and race do matter!

Histamine H2 receptor stimulation upregulates TH2 chemokine CCL17 production in human M2a macrophages Susanne Mommert, PhD, Karl Gregor, MD, Kristine.

Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment Lennart M. Roesner, PhD, Petra Kienlin, Gabriele.

Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human β-defensin-3 Kevin O. Kisich, PhD, Charles.

Eniko Sonkoly, MD, Anja Muller, MD, Antti I

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells Jean-Pierre Allam, MD, Wen-Ming Peng, MSc, Torsten Appel,

Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing.

IL-22–producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cells Kristine E. Nograles, MD,

Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with.

Rising prevalence of asthma is sex-specific in a US farming population

Distinct behavior of human Langerhans cells and inflammatory dendritic epidermal cells at tight junctions in patients with atopic dermatitis Kazue Yoshida,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation David F. Choy, BS, Daniel K. Hsu, PhD,

Tacrolimus and TGF-β act synergistically on the generation of Langerhans cells Bartlomiej Kwiek, MD, Wen-Ming Peng, MSc, Jean-Pierre Allam, MD, Andrzej.

Yuichi Teraki, MD, Aika Sakurai, MD, Seiichi Izaki, MD

Kathleen R. Bartemes, BA, Gail M. Kephart, BS, Stephanie J

T-cell receptor diversity is selectively skewed in T-cell populations of patients with Wiskott-Aldrich syndrome Junfeng Wu, MD, Dawei Liu, MS, Wenwei.

Differential expression of functional chemokine receptors on human blood and lung group 2 innate lymphoid cells Cathryn A. Weston, PhD, Batika M.J. Rana,

The usefulness of measuring tear periostin for the diagnosis and management of ocular allergic diseases Hiroshi Fujishima, MD, Naoko Okada, PhD, Kenji.

Katherine G. MacDonald, BSc, Nicholas A. J

Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2–high atopic dermatitis disease endotype Nathan Dyjack,

Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis Shunya Mashiko, BPharm, Salim Bouguermouh, MD, PhD, Manuel.

Jon Genuneit, MD, MSc Journal of Allergy and Clinical Immunology

Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis Emma Guttman-Yassky, MD, MSc, Michelle.

Sabine Leisten, MSc, Michiko K

IL-17 in atopic eczema: Linking allergen-specific adaptive and microbial-triggered innate immune response Kilian Eyerich, MD, Davide Pennino, PhD, Claudia.

Expression of the cysteinyl leukotriene receptors cysLT1 and cysLT2 in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis Chris Corrigan,

Receptor-interacting protein kinase 3 controls keratinocyte activation in a necroptosis- independent manner and promotes psoriatic dermatitis in mice

Atopic dermatitis: A practice parameter update 2012

Cellular and molecular immunologic mechanisms in patients with atopic dermatitis Thomas Werfel, MD, Jean-Pierre Allam, MD, Tilo Biedermann, MD, Kilian.

Myeloid and plasmacytoid dendritic cells in induced sputum after allergen inhalation in subjects with asthma Benny Dua, MSc, Richard M. Watson, BSc,

Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis Natalija Novak, MD,

Individual IL-3 priming is crucial for consistent in vitro activation of donor basophils in patients with chronic urticaria Thomas Gentinetta, MSc, Tatjana.

Staphylococcal exotoxins are strong inducers of IL-22: A potential role in atopic dermatitis Margarete Niebuhr, MD, Helena Scharonow, MS, Merle Gathmann,

CC chemokine receptors CCR1 and CCR4 are expressed on airway mast cells in allergic asthma Kawa Amin, PhD, Christer Janson, MD, PhD, Ilkka Harvima, MD,

Meri K. Tulic, BSc, PhD, David Andrews, MD, Maxine L

Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children Yvonne Resch, MSc, Sven Michel, MSc, Michael Kabesch, MD,

Autophagy: Nobel Prize 2016 and allergy and asthma research

Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis Marie Tauber, MD, Stefana.

Allergen-specific CD8+ T cells in peanut-allergic individuals

Matthew J. Loza, PhD, Susan Foster, PhD, Stephen P

New pathways for itching in patients with atopic dermatitis?

Baochen Shi, PhD, Nathanael J

The Editors' Choice Journal of Allergy and Clinical Immunology

Reply Journal of Allergy and Clinical Immunology

Jenny Seltmann, PhD, Lennart M

Does “autoreactivity” play a role in atopic dermatitis?

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

Biju Thomas, MD, Robert Anthony Hirst, PhD, Mina H

Human basophils may not undergo modulation by DC-SIGN and mannose receptor– targeting immunotherapies due to absence of receptors Mrinmoy Das, MSc, Caroline.

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their.

IL-31 is associated with cutaneous lymphocyte antigen–positive skin homing T cells in patients with atopic dermatitis Janine Bilsborough, PhD, Donald.

Immunopathology of atopic dermatitis

Natural history of cow’s milk allergy

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

Presentation transcript:

Expression of chemokines and chemokine receptors in lesional and nonlesional upper skin of patients with atopic dermatitis Eva Gros, MSc, Caroline Bussmann, MD, Thomas Bieber, MD, PhD, Irmgard Förster, PhD, Natalija Novak, MD Journal of Allergy and Clinical Immunology Volume 124, Issue 4, Pages 753-760.e1 (October 2009) DOI: 10.1016/j.jaci.2009.07.004 Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Quantitative changes in the relation of epidermal DC subpopulations during APTs. Contour plot analysis of Langerin-positive CD1a+ DCs (green frame) and Langerin-negative CD1a+ DCs (red frame) of a representative responder (A) and a representative nonresponder (B) before (left column), 24 hours after (middle column), and 72 hours after (right column) allergen application is shown. Values represent percentages of Langerin-positive CD1a+ cells and Langerin-negative CD1a+ cells. Values in brackets indicate the proportion of CD1a+ cells of total epidermal cells. Journal of Allergy and Clinical Immunology 2009 124, 753-760.e1DOI: (10.1016/j.jaci.2009.07.004) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Different CCR expression on epidermal DC populations of responders during APTs. Expression of CCRs on Langerin-positive CD1a+ DCs (A) and Langerin-negative CD1a+ DCs (B) before APTs (white bars) and 24 hours (green and red bars) and 72 hours (gray bars) after allergen application (n = 5) is shown. Results are given as the mean percentage of positively gated cells ± SEMs. Journal of Allergy and Clinical Immunology 2009 124, 753-760.e1DOI: (10.1016/j.jaci.2009.07.004) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Different expression of CCRs on Langerin-positive CD1a+ DCs (A) and Langerin-negative CD1a+ DCs (B) in healthy control skin (n = 8; CTR; gray bars), skin of patients with chronic AD (n = 11; red bars), and skin of patients with psoriasis (n = 8; PSO; blue bars). Results are given as the mean percentage of positive cells ± SEMs. ∗Significantly different from patients with psoriasis; #significantly different compared with the Langerin-positive CD1a+ DC population in AD skin. Journal of Allergy and Clinical Immunology 2009 124, 753-760.e1DOI: (10.1016/j.jaci.2009.07.004) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Relative expression of CC chemokine mRNA in epidermal skin of patients with AD during APTs. CCL expression in the epidermis of responders (n=5; A and B) and CCL expression in the epidermis of nonresponders (n=3; C and D) before (left column) and 24 hours (middle column) and 72 hours (right column) after allergen application are shown. Top, Panel 1 of CCLs; bottom, panel 2 of CCLs. Results are given as the mean expression of CCL mRNA normalized to healthy control skin ± SEMs. Journal of Allergy and Clinical Immunology 2009 124, 753-760.e1DOI: (10.1016/j.jaci.2009.07.004) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Different CCL mRNA expression levels in acute versus chronic AD skin lesions. Relative expression of mRNA of patients with acute AD 72 hours after APT (red bars) and patients with chronic AD (gray bars) was normalized to the mRNA level in healthy control skin. A, Panel 1 of CCLs. B, Panel 2 of CCLs. Results are given as the mean expression of CCL mRNA (n=5)±SEMs. Journal of Allergy and Clinical Immunology 2009 124, 753-760.e1DOI: (10.1016/j.jaci.2009.07.004) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 6 Relative expression of CC chemokine mRNA in the epidermis of healthy skin and skin from patients with chronic AD and psoriasis. Relative expression of mRNA in patients with chronic AD (red bars) and psoriasis (PSO; blue bars) was normalized to the mRNA level in healthy control skin (white bars; n=2). A, Panel 1 of CCLs. B, Panel 2 of CCLs ± SEMs. Journal of Allergy and Clinical Immunology 2009 124, 753-760.e1DOI: (10.1016/j.jaci.2009.07.004) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions